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ABSTRACT
Objectives: The aims of this review were to calculate
the diagnostic accuracy statistics of risk scales
following self-harm and consider which might be the
most useful scales in clinical practice.
Design: Systematic review.
Methods: We based our search terms on those used in
the systematic reviews carried out for the National
Institute for Health and Care Excellence self-harm
guidelines (2012) and evidence update (2013), and
updated the searches through to February 2015 (CINAHL,
EMBASE, MEDLINE, and PsychINFO). Methodological
quality was assessed and three reviewers extracted data
independently. We limited our analysis to cohort studies
in adults using the outcome of repeat self-harm or
attempted suicide. We calculated diagnostic accuracy
statistics including measures of global accuracy.
Statistical pooling was not possible due to heterogeneity.
Results: The eight papers included in the final analysis
varied widely according to methodological quality and the
content of scales employed. Overall, sensitivity of scales
ranged from 6% (95% CI 5% to 6%) to 97% (CI 95%
94% to 98%). The positive predictive value (PPV) ranged
from 5% (95% CI 3% to 9%) to 84% (95% CI 80% to
87%). The diagnostic OR ranged from 1.01 (95% CI
0.434 to 2.5) to 16.3 (95%CI 12.5 to 21.4). Scales with
high sensitivity tended to have low PPVs.
Conclusions: It is difficult to be certain which, if any,
are the most useful scales for self-harm risk assessment.
No scales perform sufficiently well so as to be
recommended for routine clinical use. Further robust
prospective studies are warranted to evaluate risk scales
following an episode of self-harm. Diagnostic accuracy
statistics should be considered in relation to the specific
service needs, and scales should only be used as an
adjunct to assessment.
INTRODUCTION
Self-harm is a frequent clinical challenge and
a strong predictor of future suicide.1 2 One
in six individuals presenting to hospital with
self-harm will repeat the behaviour within
1 year.2–4 Psychosocial assessment on
presentation to hospital is a key component
of recommended clinical management.5 6
Guidelines recommend that all patients pre-
senting to the hospital services with self-harm
should receive a preliminary psychosocial
assessment to determine mental capacity and
evaluate willingness to stay for further treat-
ment.5 Mental health professionals should
conduct a more comprehensive evaluation of
risk and needs at a later stage, and risk scales
are typically a core component of assess-
ments despite limited evidence of their
effectiveness.6 7 Some clinical guidelines
advise against the use of scales to determine
management, but suggest they can be used
to help structure assessments.6 Other guide-
lines recommend that only scales that have
undergone formal testing should be used as
part of clinical assessments.8
Our recent study in 32 English hospitals
found that at least 20 risk tools were in use,
suggesting that there is a lack of consensus
Strengths and limitations of this study
▪ We evaluated the diagnostic accuracy of widely
used scales which were tested for predictive use
in studies between 2002 and 2014, and included
98 600 hospital presentations of self-harm or
attempted suicide.
▪ The study provides an important critical evalu-
ation of the scales, including a wide range of
diagnostic accuracy statistics which are likely to
be useful for clinicians, commissioners and hos-
pital risk managers.
▪ We did not conduct a meta-analysis due to the
wide heterogeneity of the scales and studies
themselves.
▪ We limited our analyses to cohort studies of
adults which used repeat self-harm or attempted
suicide as an outcome, and reported measures
of diagnostic accuracy.
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over which scales are best for evaluating risk of further
self-harm.7 The uncertainty is perhaps due to methodo-
logical differences between studies and variable stan-
dards of reporting. There are a small number of reviews
which consider the predictive ability of risk scales for
repeat self-harm which may help clinicians to select the
most helpful tools6 9 10 but the information provided is
mostly limited to dual indicators such as sensitivity/spe-
ciﬁcity, positive/negative predictive values, and there is
little practical guidance for clinicians in selecting the
‘most useful tools’.
While these dual indicators are useful for determining
the predictive validity of a scale, a broader range of diag-
nostic test criteria may be helpful when selecting an
appropriate scale for clinical use given the inevitable
trade-off between sensitivity (the proportion of indivi-
duals who repeat self-harm identiﬁed by the test as high
risk) and speciﬁcity (proportion of people who did not
repeat self-harm identiﬁed as low risk by the test). For
example, a highly sensitive test might identify all patients
at risk of future self-harm but could be over inclusive
with cost and resource implications. Conversely, the
higher threshold inherent in highly speciﬁc tests may
result in false negatives and a host of deleterious conse-
quences for patients and clinical services.
We have conducted a systematic review of existing
research on risk scales to consider these issues.
The objectives were to:
1. Investigate the performance of risk scales following
self-harm or attempted suicide on a wide range of
dual measures, as well as more global measures of
accuracy.
2. Consider which might be the most useful scales fol-
lowing self-harm in clinical practice settings.
This information may be useful to clinicians, commis-
sioners and hospital risk managers, who need to critic-
ally evaluate scales for use in clinical practice.
METHOD
This study extends the reviews carried out as part of the
National Institute for Health and Care Excellence
(NICE) self-harm guidelines6 and evidence update11 on
the use of risk scales for repeat self-harm. We included
recent evidence and considered a much broader range
of diagnostic accuracy statistics than the original reviews.
Literature search
We identiﬁed studies evaluating the predictive validity of
risk scales for repeat self-harm from the NICE review on
the longer term management of self-harm and the evi-
dence update.6 11 We used the same published search
strategy11 (see online supplementary appendix 1) on
CINAHL, EMBASE, MEDLINE and PsychINFO data-
bases through to February 2015. Reference lists were
also screened and related references reviewed.
Inclusion and exclusion criteria
Consistent with the NICE self-harm evidence update,11
studies were included if they used a cohort design—the
optimal design for evaluating the diagnostic accuracy of
scales as case–control studies can overestimate diagnostic
accuracy.12 Although suicide is an extremely important
outcome following self-harm, the low base-rate hinders
predictive efforts even in high-risk populations.13 We
focused on repeat self-harm or attempted suicide as an
outcome, as the incidence rate is higher and the predic-
tion of repetition may more feasible than predicting
suicide.14 Studies were included if measures of diagnos-
tic accuracy (such as sensitivity, speciﬁcity and positive
predictive values) were reported.
Studies were excluded if the scales were validated on a
speciﬁc or restricted samples (eg, veterans, prisoners or
specialist mental healthcare population), or a sample
which did not include people presenting with self-harm
or attempted suicide. One study15 recruited a mixed
sample of people (presenting with suicide ideation or
self-harm), but since a majority of the sample (>75%)
had a history of self-harm and the study outcome was
self-harm repetition, this study was included.
Some tools were validated in more than one setting
and these were included once in the ﬁnal analysis, using
the original paper, if this met the inclusion criteria. We
did this in order to gain an indication of the ‘best-case’
scenario for different instruments (the ﬁrst study of a
new screening tool in a setting where it was developed
might be expected to give the most positive results) and
because of the potential difﬁculty of combining mea-
sures of diagnostic accuracy from different settings.
However, in order to contextualise results we did also
examine the broader performance of scales which had
been tested in multiple studies in a post hoc analysis.
Assessment of bias and study quality
Study bias was evaluated at the study level using the
QUADAS (Quality Assessment of Diagnostic Accuracy
Studies) and STARD (Standards for Reporting of
Diagnostic Accuracy) guidelines.16 17
Statistical analysis
True positives, false positives, true negatives and false
negatives were extracted from the papers by two
researchers (LQ and JC) independently, and results dis-
cussed with the third author (NK). Authors were con-
tacted where these data were unavailable.
We used a wide range of recommended diagnostic
accuracy estimates18 19 to evaluate the predictive validity
of the risk scales (box 1 and see online supplementary
appendix 2), including sensitivity (proportion of indivi-
duals who repeat self-harm identiﬁed as high risk by the
test); speciﬁcity (proportion of people who did not
repeat self-harm identiﬁed as low risk by the test); posi-
tive predictive values (probability that a person identi-
ﬁed by the test as high risk will actually go onto
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self-harm); negative predictive values (probability that a
person identiﬁed as low risk will not go onto self-harm).
Positive and negative likelihood ratios (how much
more or less likely test results are to occur in patients
who repeat self-harm vs those who do not) were also cal-
culated.19 Likelihood ratios of 1 indicate no change in
likelihood of disease or outcome (in this case repeat self-
harm). Positive likelihood ratios between 1–2, 2–5, 5–10
and >10 indicate minimal, small, moderate and large
increases in risk, respectively.19 21 Negative likelihood
ratios of 0.5–1.0, 0.02–0.5, 0.1–0.2 and <0.1 indicate
minimal, small, moderate and large decreases in risk.21
We also calculated global diagnostic statistics that sum-
marise the diagnostic performance of a test as a single
indicator,18 including the ‘number allowed to diagnose’
(number of individuals who are correctly assigned as at
high risk of repetition before one is misassigned),20 and
the diagnostic OR18 (odds of positivity in repeater rela-
tive to the odds of non-repeater). Higher values indicate
greater test discriminatory power.18 20
CIs for sensitivity and speciﬁcity were calculated using
the Wilson score method without correction.22 CIs for
positive and negative likelihood ratios were produced
using the method of Simel et al.23 The CI for the diag-
nostic OR was produced using the method published by
Armitage and Berry.24 CIs for ‘number allowed to diag-
nose’ were constructed using the method based on con-
stant χ2 boundaries from Press et al.25 Results are
unpooled due to heterogeneity in the studies.
STATA V.13.0; StataCorp. Stata Statistical Software:
Release 13. College Station, Texas: StataCorp LP, 2013)
and RevMan V.5.1 (Cochrane Collaboration)26 were
used for statistical analysis.
RESULTS
Search results
The NICE 2011 review on the longer term management of
self-harm included seven cohort studies testing the predict-
ive validity of risk scales for repeat self-harm.27–33 Four were
excluded as they did not meet our inclusion criteria—they
examined global measures rather than scales28 32—were
statistically derived without testing in a deﬁned cohort,30 or
used a restricted clinical population31 (ﬁgure 1). The NICE
Figure 1 Preferred Reporting for Systematic Reviews and Meta-Analyses flow diagram17 describing the search process for
included studies. NICE, National Institute for Health and Care Excellence.
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evidence update11 included one additional cohort study.34
The search strategy from January 2012 to February 2015
resulted in an additional 60 papers of which three were
relevant prospective cohort studies,15 35 36 and one add-
itional cohort study14 was retrieved from related references
(see ﬁgure 1). We also reran the searches for the earlier
time periods. No additional studies were identiﬁed. In
total, there were eight studies examining 11 scales which
were included in the ﬁnal analysis (ﬁgure 1).
Description of studies
The methodological characteristics of the eight
studies evaluating 11 scales are described in table 1.
Further detailed information on bias and reporting is
presented in online supplementary appendix 3. The
studies were conducted between 2002 and 2014, and
included 98 600 hospital presentations of self-harm or
attempted suicide. In terms of service context, the
studies were generally carried out across multiple sites,
the majority in publicly funded health services. Four
studies were based on self-harm emergency depart-
ment populations.15 27 35 36 Randall et al15 included a
mix of patients presenting with self-harm or suicidal
ideation. One study was based on patients treated for
self-poisoning.29 Two studies were based on hospital
presentations for suicide attempts with suicidal intent
as an inclusion criterion,33 34 and one study14 was
based on patients admitted to a medical bed after self-
harm. The length of follow-up ranged between 3 and
36 months, and outcome data was mostly ascertained
through hospital databases. The incidence of repeat
self-harm across studies ranged from 3%34 to 37%,33
possibly suggesting differences in casemix.
Four studies involved developing a tool which was
then validated on a split site or external data
set.14 27 35 36 The remainder were validation studies of
existing scales.15 29 33 34 The scales varied in length
ranging from four items (Manchester Self-harm Rule,
ReACT Self-Harm Rule 37) to 53 items for the Global
Severity Scale. Most scales included previous history of
self-harm or suicide attempts or prior psychiatric treat-
ment as items. Others scales items included personality
factors (Barratt Impulsivity Scale, clinical symptomology
(eg, Global Severity Index), drug misuse (eg, Drug
Abuse Screening Test) and variations in symptoms asso-
ciated with suicidal thoughts and behaviours (eg,
Suicide Assessment Scale).
None of the studies were explicitly formatted accord-
ing to standard guidelines (eg, STARD17) and reporting
varied across the studies. For example, there were varia-
tions across studies in the reporting of recruitment
ﬂow34 and patient characteristics,29 33 34 cross-tabulations
of raw data,14 33 34 36 CIs for diagnostic accuracy statis-
tics,,15 29 33 and use of thresholds (eg, Randall et al15 did
not use any). The database studies14 27 35 36 were the
most robustly reported according to STARD indices.
Diagnostic accuracy statistics
The full range of diagnostic accuracy statistics are pre-
sented in table 2. Figures 2 and 3 show forest plots for
sensitivity and positive predictive values, respectively.
Sensitivity (how well the test identiﬁes people who
repeat self-harm) ranged from 5.6% for the Repeated
Episodes of Self-Harm scale14 using the threshold for
the highest risk to 97% for the Manchester self-harm
rule27 95% for the ReACT Self-Harm rule,36 and 89%
for the Söderjukuest Self-harm Rule.35
Positive predictive values for the latter high sensitivity
scales were low (26%, 21% and 11%, respectively) and
were highest for the Repeated Episodes of Self-Harm
scale at the highest threshold (84%)14 followed by the
Global Severity Index (73%),15 and the Drug Abuse
Screening Test15 (ﬁgure 3). It should be noted
that the Repeated Episodes of Self-Harm score was
tested on inpatients admitted to hospital services for
self-harm.14
Positive likelihood ratios ranged from 15.7 for the
Repeated Episodes of Self-Harm scale14 at the highest
threshold (indicating a large increase in the likelihood
of repetition) to 1.0 for Söderjukuset Self-harm Rule35
and the Suicide Assessment Scale33 (indicating no
change in the likelihood of repetition) (table 2). The
diagnostic OR which presents the accuracy of a test as a
global single indicator ranged from 16.34 (Repeated
Episodes of Self-Harm scale at the highest threshold14)
and 10.77 (Manchester Self-Harm Rule27) to 1.01 for
the Södersjukuset Self-harm Rule35 and the Suicide
Assessment Scale33 (table 2).
Although the length of follow-up varied, there were
no clear patterns in relation to the prediction of shorter
versus longer term risk. As noted previously, there was a
wide variation in the methodological characteristics of
the studies and in the scales themselves.
Operational issues
Operational characteristics (ie, the time taken to do the
scale, technical speciﬁcations, ease of use, cost, staff
training, user acceptability) are important to the clinical
use of a scale and are listed in detail in table 3. Scales
with characteristics which may need to be considered
before their use include the Global Severity Index (copy-
right protected, costs associated with use, a 53-item scale
with training required prior to use).37 The Drug Abuse
Screening test may also be limited for clinicians working
with self-harm populations, as the test is designed to
assess drug-related problems.
DISCUSSION
Main findings
Risk scales are in widespread use in health services man-
aging self-harm patients.7 We examined the diagnostic
accuracy of a number of scales after self-harm and found
a wide variation in samples, follow-up, reporting, thresh-
olds, as well as differences in the content of the scales
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Table 1 Methodological characteristics of the studies
Study ID
Index test
and
comparator
tests Participants
Outcome
events
Sampling and
clinical
population
How
assessment
was
conducted Context Outcomes
Reference
standard
Follow-up
(months)
Estimates
of 95% CI
for
diagnostic
accuracy
Included
raw data
Cooper et al27
(England)
MSHR
(development
and
validation)
2095 373 Consecutive
emergency
department
self-harm
presentations
Variables
gathered as
part of routine
assessment
and extracted
from a
database
Multisite,
within
publically
funded
National
Health
Service
Self-harm
and suicide
Hospital
database
records,
searched
by
definition
6 Yes Yes
Steeg et al36
(England)
ReACT rule
(development
and
validation)
7039 2096 Consecutive
assessed and
non-assessed
emergency
department
self-harm
presentations
(England)
Variables
gathered as
part of routine
assessment
and extracted
from a
database
Multisite,
within
publically
funded
National
Health
Service
Repeat
self-harm and
suicide
Hospital
database
records,
searched
by
definition
6 Yes No
Bilèn et al35
(Sweden)
SSHR, MSHR 325 80 Consecutive
emergency
department
self-harm
presentations
Scales
completed by
treating
physician
Two large
university
hospitals with
emergency
departments,
within
publically
funded
National
Health
Service
Repeat
self-harm
Hospital
database
records,
searched
by
definition
6 Yes Yes
Spittal et al14
(Australia)
RESH
(development
and
validation)
84 659 21 672 Consecutive
inpatients
admitted for
self-harm
Large linked
data gathered
as part of
hospital
admissions
Multisite,
private and
publically
funded
hospitals
Repeat
self-harm and
suicide
combined
Hospital
database
records,
searched
6 Yes No
Continued
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Table 1 Continued
Study ID
Index test
and
comparator
tests Participants
Outcome
events
Sampling and
clinical
population
How
assessment
was
conducted Context Outcomes
Reference
standard
Follow-up
(months)
Estimates
of 95% CI
for
diagnostic
accuracy
Included
raw data
for self-harm
and suicide.
Study
variables
extracted from
database
by
definition
Carter et al29
(Australia)
ERRS 1317 188 Consecutive
self-poisoning
patients
presenting for
hospital
treatment at
centralised
referral centre
Data gathered
by toxicology
and
psychiatric
staff and rated
by psychiatric
staff
(psychiatrist,
psychiatric
registrars,
clinical nurse
consultants)
rated ERRS
variables
based on
clinical
interviews,
patient
self-report,
and case
notes
Tertiary
specialist
service for
self-poisoning
Repeat
self-poisoning
Hospital
database
records,
searched
by
definition
12 No No
Randall et al15
(Canada)
GSI, BIS
DAST
BHI, CAGE,
MSHR
157 34 Emergency
department
presentations
with self-harm
or suicidal
ideation
Trained
researcher
administered
standardised
interview and
conducted
chart reviews
Two teaching
hospitals with
largest
emergency
departments
in Edmonton
Repeat
self-harm
Hospital
records
and
telephone
call
3 Yes for
ROC
No
Waern33
(Sweden)
SUAS 162 56 Unclear
sampling,
patients
admitted to ED
Face-to-face
interviews
carried out by
three
Publically
funded
University
hospital,
Repeat
suicide
attempts and
suicide
Hospital
database
records,
search
36 No No
Continued
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Table 1 Continued
Study ID
Index test
and
comparator
tests Participants
Outcome
events
Sampling and
clinical
population
How
assessment
was
conducted Context Outcomes
Reference
standard
Follow-up
(months)
Estimates
of 95% CI
for
diagnostic
accuracy
Included
raw data
wards after a
suicide attempt
with at least
some intent to
die
psychiatric
nurses and
one
psychiatrist
within 3 days
of attempt
which is the
only hospital
to provide
emergency
services in
the study area
strategy
unclear
Bolton et al34
(Canada)
SPS, MSPS 2846 80 Consecutive
adult referrals
to psychiatric
services from
the emergency
department
Based on
C-CASA, 2
groups
established:
suicide
attempts
defined with
intent and a
reference
group without
any suicidal
ideation,
behaviour, or
preparatory
acts towards
suicide
attempts
Scales
completed by
psychiatric
residents
under
supervision
by attending
psychiatrist,
subsequent to
assessment
Two largest
tertiary care
teaching
hospitals in
Manitoba
Future
suicide
attempts
Unclear 6 No Yes
BHI, Beck Hopelessness Scale; BIS, Barratt Impulsivity Scale; C-CASA, Columbia Classification Algorithm of Suicide Assessment; CAGE, Cut down, Annoyed, Guilt, Eye-opener; DAST, Drug
Abuse Screening Test; ED, emergency department; ERRS, Edinburgh Risk of Repetition; GSI, Global Severity Index; MSHR, Manchester Self-Harm Rule; MSPS, Modified SAD PERSONS
Scale; ReACT, ReACT Self-Harm Rule; RESH, Repeated Episodes of Self-Ham score; ROC, receiver operating characteristic; SPS, SAD PERSONS Scale; SSHR, Söderjukuset Self-harm
Rule; SUAS, Suicide Assessment Scale.
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themselves. This heterogeneity was reﬂected in the vari-
ation in predictive accuracy across scales. For example,
the Manchester Self-Harm Rule was high in sensitivity
(97%) but had low positive predictive value (22%).27
Conversely, the Drug Abuse Screening Test had low sen-
sitivity (15%) but high positive predictive value (98%).15
Scales which scored highly on global measures of diag-
nostic accuracy included the Repeated Episodes of
Self-Harm scale at the highest threshold14 (16.34), the
Manchester Self-Harm Rule27 (10.77), the Drug Abuse
Screening Test15 (8.66) and the Barratt Impulsivity
Scale15 (8.25), but even these scales varied markedly in
their sensitivity from 6% for the Repeated Episodes of
Self-Harm scale14 to 97% for the Manchester Self-Harm
Scale.27
Methodological limitations
We did not conduct any meta-analyses due to the hetero-
geneity of the studies, nor did we calculate the receiver
operating characteristics of the scales as we did not have
the raw interval data. However, we provided a range of
diagnostic accuracy statistics and associated CIs, which
are useful in the critical evaluation of risk scales follow-
ing self-harm. Some scales were tested in several settings,
and we made no attempt to pool accuracy statistics
across studies. Instead, we focused on a single study for
each scale. This was the original study where this met
inclusion criteria. We did this in order to gain an indica-
tion of the scale performance under potentially optimal
conditions and because of the difﬁculty in pooling
results from different settings.
Two scales in particular had been tested in multiple
studies and settings (Edinburgh Risk of Repetition Scale
and the Manchester Self-Harm Rule).9 Sensitivities for
the Edinburgh Risk of Repetition Scale ranged from
26% to 41%, and speciﬁcities ranged from 84% to 91%
in an early study.44 A further validation study conducted
in Australia provided similar results (sensitivity: 26%,
speciﬁcity: 84%).29 Broadly similar results were found in
Oxford,45 for the Edinburgh Risk of Repetition Scale,
but sensitivities were lower when tested on a 12-month
rather than a 6-month follow-up, and ranged from 3%
to 16%.45
The Manchester Self-Harm Rule was validated in
Sweden,35 Manchester28 36 and Canada.15 The results
were similar to those of Cooper et al27 in demonstrating
the high sensitivity (94%, 94%, 98% and 95.1% for the
studies, respectively) and low speciﬁcity (18%, 26%, 17%
and 14.7%, respectively) of the scale.
We were keen to replicate the searches carried out as
part of UK national guidance as far as possible. In some
senses, the current paper was intended as an update of
the review carried out as part of the NICE self-harm
(longer term management guidelines), and we were
constrained by the original methodology. Some well-
known scales were not included in the NICE review6 11
on the basis of the prespeciﬁed inclusion criteria, for
example, because they did not explicitly report
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diagnostic accuracy outcomes), and therefore did not
ﬁnd their way into the current paper.44 46 Data in the
papers45 46 (sensitivities ranging from 5.3% to 14.6%
and speciﬁcities ranging from 93% to 97%) and from
subsequent reviews9 indicate that in any case these older
studies and scales did not have superior results to those
described in our study. Inclusion of these additional
scales would not have changed our ﬁndings. Although
we used a published search strategy,6 11 there is a possi-
bility that additional scales were excluded due to the
search criteria and of publication bias in the included
studies as some studies with negative results may not be
widely accessible.
We considered the performance of these scales only
in relation to people who self-harmed rather than the
wider general or clinical population. However, this is an
important clinical group, and in many settings risk scales
are an intrinsic part of their management. Our main
outcome was repeated self-harm or attempted suicide
rather than suicide. While suicide is extremely import-
ant, because it is a relatively low-frequency event, it is
much harder to predict. This is reﬂected in the poorer
performance of scales in relation to suicide than repeat
self-harm as outlined in UK guidance.6 Only two of the
studies included in this review also reported suicide out-
comes.27 36 The Manchester Self-Harm Rule identiﬁed
100% of the 22 suicide deaths that occurred within the
6-month follow-up period.27 The ReACT Rule identiﬁed
60 of the 66 suicide deaths (91%) in the derivation data
set and 23 of 26 (88%) in the test data set within
6 months of the index episode.36 These results indicate
high sensitivity, but this is once again at the expense of
low speciﬁcity and poor positive predictive value. Two
other studies combined suicide and repeat self-harm as
an outcome,14 33 and deaths by suicide were not
included in the remaining studies.15 29 34 35
Clinical implications
What is the most useful scale following self-harm?
The use of scales is dependent on multiple factors. The
scales are not directly comparable due to differences in
the incidence of repeat self-harm across studies and
methodological quality. Many of the studies were con-
ducted in high-income countries in centrally funded
health services,15 27 33–36 and so the ﬁndings may not be
applicable to different settings. The Repeated Episodes
of Self-Harm Scale was developed on an inpatient
sample which is unlikely to be transferable to emergency
department services. The performance of the scales may
be additionally inﬂuenced by cultural contexts. For
example, the Barratt Impulsivity scale15 40 was developed
in the USA, and the terminology of some of the items
may reduce the performance of the scale in other cul-
tures (eg, ‘I squirm at plays or lectures’). There is also a
challenging balance when selecting scales based on diag-
nostic accuracy statistics, and no scale performed well
across all indices.
Global indicators such as the diagnostic OR provide
the strength of the association between the exposure
and the disease and are readily interpreted by clinicians.
False-positive and false-negative results are equally
weighted, which is advantageous for research and
meta-analyses, but may limit clinical use as clinicians
cannot evaluate the scale on the basis of sensitivity and
speciﬁcity.18 The scales which had the highest global
diagnostic ORs were the Repeated Episodes of
Self-Harm scale at the highest threshold (16.34) and the
Manchester Self-Harm Rule (10.77).14 27
Figure 2 Forest plot of sensitivity and 95% CIs for individual
scales. BIS, Barratt Impulsivity Scale; DAST, Drug Abuse
Screening Test; ERRS, Edinburgh Risk of Repetition; GSI,
Global Severity Index; MSHR, Manchester Self-Harm Rule;
MSPS, Modified SAD PERSONS Scale; ReACT, ReACT
Self-Harm Rule; RESH, Repeated Episodes of Self-Ham
score; SoSHR, Söderjukuset Self-harm Rule; SUAS, Suicide
Assessment Scale.
Figure 3 Forest plot of positive predictive values and 95%
CIs for individual scale. BIS, Barratt Impulsivity Scale; DAST,
Drug Abuse Screening Test; ERRS, Edinburgh Risk of
Repetition; GSI, Global Severity Index; MSHR, Manchester
Self-Harm Rule; MSPS, Modified SAD PERSONS Scale;
ReACT, ReACT Self-Harm Rule; RESH, Repeated Episodes
of Self-Ham score; SoSHR, Söderjukuset Self-harm Rule;
SUAS, Suicide Assessment Scale.
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Table 3 Scale operational factors
Instrument
Purpose of
instrument Cost Description Time (min) Copyright Administration Training
Study
reference
Original
scale
reference
The
Manchester
Self-Harm
Rule
Risk-stratification
model for use with
ED staff in the
assessment of
self-harm to
discriminate between
patients and higher
vs lower risk of
repetition or
subsequent suicide
by 6 months
Free 4 screening items,
dichotomous answers
(history of self-harm,
prior psychiatric
treatment,
benzodiazepine
overdose, current
psychiatric treatment)
(1=present, 0=absent),
positive answer is a
positive result
5 No Paper and pen Limited
training
necessary
Cooper
et al27
Cooper
et al27
The ReACT
Self-Harm
Rule
Screening tool to
identify patients at
higher risk of repeat
self-harm suicide
within 6 months of
ED self-harm
presentation
Free 4 items (recent
self-harm (in the past
year), Alone of
homeless (living
status), cutting used as
a method of harm, and
treatment for a current
psychiatric disorder),
presence of one or
more of these items
classifies patient as at
higher risk of repeat
self-harm/suicide within
6 months
5 No Paper and pen Limited
training
necessary
Steeg
et al36
Steeg
et al36
The RESH
Self-Harm tool
Designed to assist
clinicians in clinical
management of
self-harm patients
Free 4 main items with an
assigned weight:
number of prior
episodes (0, 1, 2, 3, 4,
5, 6 or more), time
between episodes
(1–60 days, 61 days
to 12 months,
> 12 months),
psychiatric diagnosis in
the last 12 months
(substance misuse
disorder, depression,
anxiety, eating
disorder, personality
Unknown No Paper and Pen Unknown Spittal
et al14
Spittal
et al14
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Table 3 Continued
Instrument
Purpose of
instrument Cost Description Time (min) Copyright Administration Training
Study
reference
Original
scale
reference
disorder), and
psychiatric stay in the
last 12 months. The
RESH scale was
constructed using a
weighted scoring
algorithm based on the
log ORs based on 0 to
20. It has five cut-off
points ranging from
low-risk to high-risk that
can be applied to
different interventions
The Global
Severity Index
(GSI)
The GSI symptom
scale is a component
of the Brief Symptom
Inventory (BSI). Also
a global indicator, the
Symptom
Checklist-90-Revised
(SCL-90-R) is
‘designed to help
quantify a patients
severity-of-illness and
provides a single
composite score for
measuring the
outcome of a
treatment programme
based on reducing
symptom severity’
(Pearson
Assessments)
£118.32 per
50 answer
sheets with
test items,
50 profile
forms and 2
worksheets
(£935+vat
for 500)
53-item self-report on
5-point rating scale.
9 symptom dimensions
(somatisation,
Obsessive-compulsive,
Interpersonal
sensitivity, Depression,
Anxiety, Hostility,
Phobic Anxiety,
Paranoid Ideation,
Psychoticism)
Global Indices (Global
severity index, Positive
Symptom Distress
Index, Positive
Symptom total). Also a
component of the
90-item SCL-90-R (12–
15 min to complete)
8–10 Pearson
Assessments
Q Local
Software,
Mail-in scoring
service, Hand
scoring, or
optimal Scan
Scoring
B, Q1, Q2
level
Randall
et al15
Derogitis
and
Melisaratos
37
The SAD
PERSONS
scale
Educational tool for
medical students to
determine suicide risk
Free 10-item mnemonic
consisting of risk
factors based on
literature review (male
sex, age, depression,
previous attempt,
excess alcohol or
5–10 No Paper and pen Limited
training
necessary
Bolton
et al34
Patterson
et al38
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Table 3 Continued
Instrument
Purpose of
instrument Cost Description Time (min) Copyright Administration Training
Study
reference
Original
scale
reference
substance abuse,
rational thinking loss,
social supports lacking,
organised plan, no
spouse, sickness).
Items scored 1 if
present, 0 if absent.
Cut-off points: 3
categories of suicide
risk, low, moderate,
and high (0–4, 5–6 and
7–10, respectively)
The Modified
SAD
PERSONS
Suicide assessment
in the ED
10-item scale. Modified
SAD PERSONS by
adding five additional
criteria (feelings of
hopelessness, history
of psychiatric care,
drug addiction, a
‘serious’ attempt, and
affirmative or
ambivalent answers
when questioned about
future intent regarding
suicide. Four scale
items are weighted with
scores of 2 to give a
total possible score of
14. Cut-off points: low
(0–5), moderate (6–8),
and high (9–14)
5–10 No Paper and pen Limited
training
necessary
Bolton
et al34
Hockberger
and
Rothstein39
The Barratt
Impulsivity
Scale
Designed to assess
the personality trait of
impulsiveness
Free 30 items based on
personality. Self-report.
Responses scored on
a 4-point likert scale.
Responses summed to
total score
10 No Paper and pen None Randall
et al15
Patton
et al40
The Drug
Abuse
Screening Test
Designed to identify
patients who are
abusing drugs, also
Free 28-items self-report
Responses are
dichotomous (1=yes,
5 No Paper and Pen Adherence to
instructions
for
Randall
et al15
Skinner41
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Table 3 Continued
Instrument
Purpose of
instrument Cost Description Time (min) Copyright Administration Training
Study
reference
Original
scale
reference
to provide a
quantitative index
score if the degree of
problems related to
drug use and misuse
0=no), except for items
4, 5, and 7 which are
reverse coded. The
scale is unidimensional
with a total score
calculated from
summing all the items
that are positive in
relation to increased
drug use. Cut-off
scores of six to 11 are
used for identifying
patients with drug
abuse/ misuse
problems, whereas of
16 or above is
considered as severe
drug abuse or
dependency
administration
and scoring
provided with
the scale
The Suicide
Assessment
Scale
Designed to be
sensitivity to change
in suicidality over
time and in treatment
Free 20 items, on a 0–4
likert scale summed to
arrive at a maximum
score of 80. Five main
areas covered: (affect
(5 items), bodily states
(5 items), control and
coping (5 items),
emotional reactivity,
suicidal thoughts and
behaviour (5 items).
Clinician and self-report
versions available
>30=high
risk
No Paper and pen Instructions
available
Waern
et al33
Stanley
et al42
Niméus
et al43
Edinburgh
Risk of
Repetition
Scale
Designed to identify
patients at risk of
repeat self-harm
Free 11 items (previous
self-harm, personality
disorder, alcohol,
previous psychiatric
care, unemployment,
social class, drug
Men
>8=high
risk
Women
>6=high
risk
No Paper and Pen None Carter
et al29
Kreitman
and
Foster44
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The balance between sensitivity and speciﬁcity is
dependent on various factors such as resources, purpose
of the test and stage of treatment. Clinicians may prefer
a test high in sensitivity to capture as many repeat self-
harm episodes as possible, for example, the Manchester
Self-Harm Rule27 or the ReACT Self-Harm rule.36
Highly sensitive tests are sometimes used to screen
patients or can assist in ‘ruling out’ patients as the possi-
bility of a false negative is relatively low.19 The
Manchester Self-Harm rule was also validated in other
prospective cohort studies and similar sensitivities and
speciﬁcities were reported.15 28 35 36 However, the
ReACT Self-Harm Rule36 and Manchester Self-Harm
Rule27 have poor speciﬁcity and positive predictive
values, and there is a possibility that many patients could
be false positives (ie, incorrectly labelled as at high risk),
which has cost and resource implications.47
Scales high in speciﬁcity, such as the Repeated
Episodes of Self-Harm scale at the highest threshold,14
may be useful for a later stage of assessment or if treat-
ment outcomes are expensive, medically invasive or bur-
densome to the patients. Scales high in speciﬁcity can
also be used to ‘rule in’ patients, as the number of false
positives is low (so people labelled as at high risk are
quite likely to be at high risk). However, the clinical utility
of high speciﬁcity scales may be limited because of the
small numbers of patients who screen positive, and the
fact that the high risk of the patients who reach the
threshold is already fairly obvious on the basis of conven-
tional clinical risk factors (eg, for the Repeated Episodes
of Self-Harm Scale at the highest threshold, the small
number of patients who have multiple prior episodes of
self-harm, psychiatric diagnosis and recent psychiatric
hospitalisation are clearly at elevated risk14). The sensitiv-
ities of such scales in this study were poor, and there is a
possibility of false negatives (people being labelled as at
low risk when they are actually at high risk).
Clinicians might consider scales with high positive pre-
dictive values such as the Repeated Episodes of
Self-Harm scale at the highest threshold, as positive pre-
dictive values are a measure of the probability that an
individual at high risk actually goes on to repeat self-
harm. However, positive predictive values are affected by
how common the outcome is, which affects their trans-
ferability to clinical settings with a different incidence of
repeat self-harm. The scales with high positive predictive
values (eg, Repeated Episodes of Self-Harm scale at high
threshold,14 and Global Severity Index15 were also low in
sensitivity, which is a further consideration when the
evaluating the usefulness of scales for clinical practice.
Scales can be evaluated using likelihood ratios (prob-
ability of a speciﬁc result among people who repeat self-
harm divided by the probability of a given result among
people who do not repeat self-harm), and they are
widely used in evidence-based medicine.48 They are
advantageous in evaluating scales, as information from
both sensitivity and speciﬁcity is used, they are not
affected by prevalence, and they are fairly easy to
Ta
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interpret (eg, >10 indicates a useful test). The Repeated
Episodes of Self-Harm scale at the highest threshold had
the highest likelihood ratio (15.7),14 which indicates that
the highest risk threshold is useful in predicting repeat
self-harm, but had low sensitivity (6%) which limits the
scale for screening purposes. There are limitations in
the use of likelihood ratios for clinical practice. The esti-
mation of baseline risk may be dependent on clinical
experience, accurate estimates of prevalence, and famil-
iarity in expressing risk in terms of probabilities.49
Clinicians may prefer to use a scale for predicting
completed suicide, but scales which do so are perhaps
more likely to have high sensitivity and be over inclusive
(eg, the Manchester Self-Harm Rule27 and the ReACT
Self-Harm Rule.36 Only two of the studies in this
review27 36 evaluated suicide separately as an outcome,
and the predictive utility of the scales for suicide needs
to be investigated further.
We were unable to examine the predictive usefulness
of the scales in predicting shorter versus longer term
risk of self-harm repetition due to the heterogeneity of
the scales and methodological characteristics. The use
of scales in predicting shorter vs longer term risk is clin-
ically important and should be investigated further
using prospective cohort studies.
CONCLUSION
On the basis of our review, it is clear that no scale appears
to perform sufﬁciently well to be used routinely. The
limitations of risk scales in clinical practice are well docu-
mented, and it is suggested that the clinical focus should
be on ‘conducting comprehensive clinical assessments of
each patient’s situation and needs’ rather than the cat-
egorisation of patients into high-risk and low-risk categor-
ies (p.463).50–52 The focus on risk assessment can detract
from the therapeutic relationship,53 and studies have
reported that patients and staff can ﬁnd assessments with
scales an adverse experience.8 However, risk scales con-
tinue to be widely used in self-harm services with hospi-
tals commonly developing local instruments.7 Traditional
paradigms which simply aim to balance sensitivity versus
speciﬁcity may be of limited usefulness in the develop-
ment of risk scales for use following self-harm. Future
research should involve head-to-head comparisons. This
may have more validity than comparing scales used in dif-
ferent patient groups across different settings. Studies
need to determine the effectiveness of risk scales using
robust predictive accuracy cohort studies that are clearly
reported according to STARD criteria.54 Until then, it is
difﬁcult to evaluate what the most useful instruments are
and, in line with clinical guidance, scales should not be
used in isolation to determine management or to predict
risk of future self-harm.6
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